{"disease":{"id":"idh-mutation","name":"idh mutation"},"drugs":{"marketed":[{"drug_id":"olutasidenib","indication_name":"Refractory acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"olutasidenib","indication_name":"Relapsing acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04369287","title":"Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia","phase":"","overall_status":"UNKNOWN","enrollment_count":654,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT02381886","title":"A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06127407","title":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Servier Bio-Innovation LLC","has_results":false},{"nct_id":"NCT03684811","title":"A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Forma Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03749187","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06707493","title":"Ivosidenib as Post-HSCT Maintenance for AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03434262","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07032727","title":"Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03914742","title":"BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT03383575","title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03991832","title":"Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05345002","title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Stephen Bagley, MD, MSCE","has_results":false},{"nct_id":"NCT04233788","title":"Metabolic Characterization of Space Occupying Lesions of the Brain","phase":"","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT06501625","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03683433","title":"Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04522895","title":"IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT07007949","title":"a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04740190","title":"Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06611839","title":"Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04092179","title":"Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06636162","title":"Window of Opportunity Study of DSP-0390 in Gliomas","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03564821","title":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06782542","title":"Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Justin Watts, MD","has_results":false},{"nct_id":"NCT04056910","title":"Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Jason J. Luke, MD","has_results":true},{"nct_id":"NCT07286292","title":"Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institut de Recherches Internationales Servier (I.R.I.S.)","has_results":false},{"nct_id":"NCT05814536","title":"IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"AnHeart Therapeutics Inc.","has_results":false},{"nct_id":"NCT04281498","title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"John Mascarenhas","has_results":true},{"nct_id":"NCT03303950","title":"Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT04955938","title":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05061251","title":"Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03881735","title":"Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}